Summary

Veterinary Anti-infectives Market Summary

The global veterinary anti-infectives market was estimated at USD 8.26 billion in 2024 and is projected to reach USD 14.37 billion by 2033, growing at a CAGR of 6.5% from 2025 to 2033. Key factors expected to drive the market include the rise in animal infectious diseases, developing research initiatives, a boost to prudent antibiotic use, increasing regulatory approvals, and growing applications of Artificial Intelligence (AI).

One of the foremost drivers is the growing integration of artificial intelligence (AI) in veterinary practices. Educational institutions, animal welfare bodies, and commercial players are adopting AI to streamline clinical decision-making, assist in early disease detection, identify treatment gaps, and even accelerate veterinary drug discovery. AI also offers potential for predictive modeling in outbreak surveillance, helping to rationalize anti-infective use amid rising concerns of antimicrobial resistance (AMR).

Another critical factor is the increasing global prevalence of infectious diseases in companion and livestock animals. For example, India-a leading dairy-producing country-witnessed a severe outbreak of Lumpy Skin Disease in 2023, which infected nearly 2.95 million cattle and resulted in over 155,000 deaths across 15 states. Similarly, in the U.S., one of the world's top beef producers, a recent outbreak of highly pathogenic avian influenza (HPAI) among cattle saw over 250 beef samples from 38 states testing positive as of May 2024. South Africa also faced a 30% drop in egg production and had to cull over a million poultry in 2023 due to HPAI. These disease outbreaks are directly escalating the demand for effective anti-infective therapies.

Rising antimicrobial resistance (AMR) is also shaping the market, prompting stricter regulatory surveillance. In June 2025, India's Central Drugs Standard Control Organisation (CDSCO) launched a nationwide initiative to monitor antibiotic use in livestock. It established inter-agency collaborations and mandated AMU (antimicrobial use) data reporting to combat misuse and overuse of antibiotics, which can drive the development and adoption of newer, more targeted anti-infectives.

Intensive R&D and industry collaborations support these regulatory developments. In March 2024, Zoetis partnered with Blacksmith Medicines to develop novel antibiotics to circumvent bacterial resistance by selectively targeting drug-resistant strains. Likewise, discoveries such as bird flu's zoonotic shift to cattle-uncovered by a veterinarian in Texas-open new avenues for therapeutic innovation in livestock disease management.

Additionally, the growth of generic and value-added veterinary medicines is expanding market accessibility. The 2024 European Market Study by Access VetMed revealed that generics account for around 50% of all veterinary product authorizations, with significant traction in anti-infectives and antiparasitics. Despite regulatory burdens like EU Regulation 2019/6, especially for SMEs, the sector remains growing, particularly for companion animal products and alternative administration routes.

Overall, the rise in infectious disease outbreaks, regulatory tightening on antimicrobial use, technological innovations like AI, and increased investment in R&D and generics significantly propel the veterinary anti-infectives market. These forces are expected to meet current treatment demands and ensure veterinary antimicrobial therapy's long-term sustainability and efficacy.

Global Veterinary Anti-infectives Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global veterinary anti-infectives market report based on animal type, product, route of administration, type, distribution channel & region.

• Animal Type Outlook (Revenue, USD Million, 2021 - 2033)
• Livestock Animal
o Poultry
o Swine
o Cattle
o Sheep & Goats
o Fish
o Others
• Companion Animal
o Dogs
o Cats
o Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Antimicrobial
o Tetracyclines
o Penicillin
o Cephalosporins
o Macrolides
o Quinolones
o Others
• Antifungals
• Antivirals
• Antiparasitic
• Others
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Oral
• Injectable
• Topical
• Type Outlook (Revenue, USD Million, 2021 - 2033)
• OTC
• Prescription
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital/ Clinic Pharmacy
• Retail Pharmacies
• E-commerce
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o Japan
o India
o China
o South Korea
o Australia
o Thailand
• Latin America
o Brazil
o Argentina
• Middle East and Africa (MEA)
o South Africa
o Saudi Arabia
o UAE
o Kuwait

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. GVR’s Internal Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.4. Information/Data Analysis
1.5. Market Formulation & Visualization
1.6. Data Validation & Publishing
1.7. Model Details
1.7.1. Commodity flow analysis
1.7.2. Global Market: CAGR Calculation
1.8. List of Secondary Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Veterinary Anti-infectives Market Variable Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market
3.1.2. Ancillary Market
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rise in Infectious Diseases Among Animals
3.2.1.2. Growing Research Initiatives
3.2.1.3. Boost to Prudent Use of Antibiotics
3.2.1.4. Increasing Regulatory Approvals
3.2.1.5. Growing Applications of AI
3.2.2. Market Restraint Analysis
3.2.2.1. Drop in Consumption
3.2.2.2. Emerging Drug Resistance
3.2.2.3. Stringent Regulations
3.2.3. Market Opportunity Analysis
3.2.4. Market Challenge Analysis
3.3. Veterinary Anti-infectives Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitution
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political & Legal landscape
3.3.2.2. Economic and Social landscape
3.3.2.3. Technological landscape
3.3.2.4. Environmental landscape
3.3.3. Regulatory Framework by Key Countries
3.3.4. Estimated Animal Population, by Key Species, by Key Countries, 2021-2023
3.3.5. Prevalence of Key Infectious Diseases, by key species, by key countries (2024)
3.3.6. COVID-19 Impact Analysis
Chapter 4. Veterinary Anti-infectives Market: Animal Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Veterinary Anti-infectives Market: Animal type Movement Analysis
4.3. Veterinary Anti-infectives Market Size & Trend Analysis, by animal type, 2021 to 2033 (USD Million)
4.4. Livestock Animal
4.4.1. Production Animal Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.2. Poultry
4.4.2.1. Poultry Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3. Swine
4.4.3.1. Swine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.4. Cattle
4.4.4.1. Cattle Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.5. Sheep & Goats
4.4.5.1. Sheep & Goats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.6. Fish
4.4.6.1. Fish Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.7. Others
4.4.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Companion Animal
4.5.1. Companion Animal Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.2. Dogs
4.5.2.1. Dogs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.3. Cats
4.5.3.1. Cats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.4. Others
4.5.4.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Veterinary Anti-infectives Market: Product Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Veterinary Anti-infectives Market: Product Movement Analysis
5.3. Veterinary Anti-infectives Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
5.4. Antimicrobials
5.4.1. Antimicrobials Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.2. Cephalosporins
5.4.2.1. Cephalosporins Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.3. Tetracyclines
5.4.3.1. Tetracyclines Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.4. Penicillin
5.4.4.1. Penicillin Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.5. Macrolides
5.4.5.1. Macrolides Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.6. Others (Quinoles, sulfonamides, polymyxins)
5.4.6.1. Others (Quinoles, sulfonamides, polymyxins) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Antifungals
5.5.1. Antifungals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Antivirals
5.6.1. Antivirals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Others
5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Veterinary Anti-infectives Market: By Route of Administration Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Veterinary Anti-infectives Market: By Route of Administration Movement Analysis
6.3. Veterinary Anti-infectives Market Size & Trend Analysis, by route of administration, 2021 to 2033 (USD Million)
6.3.1. Oral
6.3.1.1. Oral Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.2. Injectables
6.3.2.1. Injectables Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.3. Others
6.3.3.1. Topical Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Veterinary Anti-infectives Market: By Type Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Veterinary Anti-infectives Market: By Type Movement Analysis
7.3. Veterinary Anti-infectives Market Size & Trend Analysis, by type, 2021 to 2033 (USD Million)
7.3.1. OTC
7.3.1.1. OTC Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3.2. Prescription
7.3.2.1. Prescription Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Veterinary Anti-infectives Market: By Distribution Channel Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Veterinary Anti-infectives Market: By Distribution Channel Movement Analysis
8.3. Veterinary Anti-infectives Market Size & Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
8.3.1. Hospital/Clinic Pharmacy
8.3.1.1. Retail Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.2. Retail Pharmacies
8.3.2.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.3. E-commerce
8.3.3.1. E-commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Veterinary Anti-infectives Market: Regional Estimates & Trend Analysis
9.1. Regional Dashboard
9.2. Veterinary Anti-infectives Market Share, By Region, 2024 & 2033, USD Million
9.3. Regional Outlook
9.4. North America
9.4.1. North America Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.4.2. U.S.
9.4.2.1. Key Country Dynamics
9.4.2.2. U.S. Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.4.3. Canada
9.4.3.1. Key Country Dynamics
9.4.3.2. Canada Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.4.4. Mexico
9.4.4.1. Key Country Dynamics
9.4.4.2. Mexico Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.5. Europe
9.5.1. Europe Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.5.2. UK
9.5.2.1. Key Country Dynamics
9.5.2.2. UK Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.5.3. Germany
9.5.3.1. Key Country Dynamics
9.5.3.2. Germany Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.5.4. France
9.5.4.1. Key Country Dynamics
9.5.4.2. France Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.5.5. Italy
9.5.5.1. Key Country Dynamics
9.5.5.2. Italy Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.5.6. Spain
9.5.6.1. Key Country Dynamics
9.5.6.2. Spain Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.5.7. Denmark
9.5.7.1. Key Country Dynamics
9.5.7.2. Denmark Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.5.8. Sweden
9.5.8.1. Key Country Dynamics
9.5.8.2. Sweden Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.5.9. Norway
9.5.9.1. Key Country Dynamics
9.5.9.2. Norway Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.6. Asia Pacific
9.6.1. Asia Pacific Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.6.2. Japan
9.6.2.1. Key Country Dynamics
9.6.2.2. Japan Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.6.3. China
9.6.3.1. Key Country Dynamics
9.6.3.2. China Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.6.4. India
9.6.4.1. Key Country Dynamics
9.6.4.2. India Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.6.5. Australia
9.6.5.1. Key Country Dynamics
9.6.5.2. Australia Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.6.6. South Korea
9.6.6.1. Key Country Dynamics
9.6.6.2. South Korea Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.6.7. Thailand
9.6.7.1. Key Country Dynamics
9.6.7.2. Thailand Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.7. Latin America
9.7.1. Latin America Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.7.2. Brazil
9.7.2.1. Key Country Dynamics
9.7.2.2. Brazil Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033
9.7.3. Argentina
9.7.3.1. Key Country Dynamics
9.7.3.2. Argentina Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.8. Middle East & Africa
9.8.1. Middle East & Africa Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.8.2. South Africa
9.8.2.1. Key Country Dynamics
9.8.2.2. South Africa Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.8.3. Saudi Arabia
9.8.3.1. Key Country Dynamics
9.8.3.2. Saudi Arabia Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.8.4. UAE
9.8.4.1. Key Country Dynamics
9.8.4.2. UAE Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.8.5. Kuwait
9.8.5.1. Key Country Dynamics
9.8.5.2. Kuwait Veterinary Anti-infectives Market Estimates And Forecasts, 2021 - 2033 (USD Million)
Chapter 10. Competitive Landscape
10.1. Market Participant Categorization
10.2. Company Market Position Analysis/ Heap Map Analysis
10.3. Company Profiles
10.3.1. Zoetis
10.3.1.1. Participant’s Overview
10.3.1.2. Financial Performance
10.3.1.3. Product Benchmarking
10.3.1.4. Strategic Initiatives
10.3.2. Boehringer Ingelheim
10.3.2.1. Participant’s Overview
10.3.2.2. Financial Performance
10.3.2.3. Product Benchmarking
10.3.2.4. Strategic Initiatives
10.3.3. Merck & Co. Inc.
10.3.3.1. Participant’s Overview
10.3.3.2. Financial Performance
10.3.3.3. Product Benchmarking
10.3.3.4. Strategic Initiatives
10.3.4. Dechra Pharmaceuticals Plc.
10.3.4.1. Participant’s Overview
10.3.4.2. Financial Performance
10.3.4.3. Product Benchmarking
10.3.4.4. Strategic Initiatives
10.3.5. Elanco Animal Health
10.3.5.1. Participant’s Overview
10.3.5.2. Financial Performance
10.3.5.3. Product Benchmarking
10.3.5.4. Strategic Initiatives
10.3.6. Ceva Sante Animale
10.3.6.1. Participant’s Overview
10.3.6.2. Financial Performance
10.3.6.3. Product Benchmarking
10.3.6.4. Strategic Initiatives
10.3.7. Virbac
10.3.7.1. Participant’s Overview
10.3.7.2. Financial Performance
10.3.7.3. Product Benchmarking
10.3.7.4. Strategic Initiatives
10.3.8. Biogenesis Bago
10.3.8.1. Participant’s Overview
10.3.8.2. Financial Performance
10.3.8.3. Product Benchmarking
10.3.8.4. Strategic Initiatives
10.3.9. Vetoquinol
10.3.9.1. Participant’s Overview
10.3.9.2. Financial Performance
10.3.9.3. Product Benchmarking
10.3.9.4. Strategic Initiatives
10.3.10. Calier
10.3.10.1. Participant’s Overview
10.3.10.2. Financial Performance
10.3.10.3. Product Benchmarking
10.3.10.4. Strategic Initiatives
10.3.11. Norbrook Laboratories
10.3.11.1. Participant’s Overview
10.3.11.2. Financial Performance
10.3.11.3. Product Benchmarking
10.3.11.4. Strategic Initiatives
10.4. Strategy Mapping
10.4.1. Mergers & Acquisitions
10.4.2. Partnerships & Collaborations
10.4.3. Expansion
10.4.4. Product launch
10.4.5. Product Approval
10.4.6. Others
10.5. List of Key Companies
10.5.1. List of Manufacturers
10.5.2. List of Distributors